TTK Healthcare Ltd. Stock Hits 52-Week Low Amidst Continued Downtrend

Price Movement and Market Context

On 22 Jan 2026, TTK Healthcare opened with a notable gap up, rising 8.37% to an intraday high of Rs.1084.2. However, the stock reversed sharply during the session, falling to an intraday low of Rs.965, representing a 3.54% drop from the previous close and establishing a new 52-week low. The stock closed with a day change of -2.13%, underperforming its sector by 2.62%. This decline extends a three-day losing streak, during which the stock has delivered a cumulative negative return of 2.2%.

Volatility was elevated, with an intraday weighted average price volatility of 9.93%, underscoring the unsettled trading environment. Furthermore, TTK Healthcare is currently trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling persistent bearish momentum.

In contrast, the broader market showed mixed signals. The Sensex opened higher at 82,459.66, gaining 550.03 points (0.67%) but later retreated to 81,994.02, a marginal 0.1% increase. Despite this, the Sensex has been on a three-week losing streak, shedding 4.39% in that period. Mid-cap stocks led the market rally, with the BSE Mid Cap index advancing 0.84% on the day.

Long-Term Performance and Financial Metrics

TTK Healthcare’s one-year performance has been notably weak, with the stock declining 26.66%, in stark contrast to the Sensex’s 7.32% gain over the same period. The stock’s 52-week high stands at Rs.1402, highlighting the extent of the recent price erosion.

Financially, the company has exhibited modest growth, with net sales increasing at an annualised rate of 7.36% over the past five years. However, recent quarterly results have been subdued. The Profit Before Tax excluding other income (PBT LESS OI) for the quarter stood at Rs.2.29 crore, a sharp decline of 58.29% compared to the previous period. Notably, non-operating income accounted for 89.25% of the total Profit Before Tax, indicating limited contribution from core business activities.

Shareholding and Market Perception

Despite its size, TTK Healthcare commands a minimal presence in domestic mutual fund portfolios, with holdings amounting to only 0.01% of the company’s equity. Given that domestic mutual funds typically conduct thorough research and maintain significant stakes in companies they favour, this limited exposure may reflect a cautious stance towards the stock’s valuation or business prospects.

Over the last three years, the stock has underperformed the BSE500 index across multiple time frames, including the one-year and three-month periods, reinforcing concerns about its relative market standing.

Valuation and Financial Ratios

TTK Healthcare maintains a low average debt-to-equity ratio of zero, indicating a debt-free capital structure. The company’s return on equity (ROE) stands at 6.5%, which, while modest, is accompanied by an attractive price-to-book (P/B) ratio of 1.3. However, the stock trades at a premium relative to its peers’ historical valuations.

Profit growth over the past year has been positive, with a 9.3% increase, yet this has not translated into share price appreciation. The company’s price/earnings to growth (PEG) ratio is 2.2, suggesting that the market may be pricing in slower growth or higher risk compared to earnings expansion.

Mojo Score and Analyst Ratings

According to MarketsMOJO’s latest assessment dated 21 Jul 2025, TTK Healthcare’s Mojo Score stands at 37.0, categorised under a Sell grade. This represents a downgrade from the previous Hold rating, reflecting deteriorated fundamentals and market sentiment. The company’s market cap grade is rated at 3, indicating a mid-tier capitalisation relative to the broader market.

The downgrade aligns with the company’s subdued growth metrics and recent financial results, which have not met expectations. The combination of declining share price, underwhelming profitability, and limited institutional interest contributes to the cautious stance reflected in the rating.

Summary of Key Price and Performance Metrics

To summarise, TTK Healthcare’s stock has experienced a notable decline, reaching Rs.965 today, its lowest level in the past year. The stock’s recent volatility and failure to sustain gains despite an initial gap up highlight ongoing market uncertainty. Its underperformance relative to the Sensex and sector indices, combined with modest financial growth and a cautious rating outlook, frame the current market environment for the company.

While the company’s balance sheet remains strong with no debt and a reasonable ROE, these factors have not been sufficient to counterbalance the broader concerns reflected in the share price and analyst assessments.

Unlock special upgrade rates for a limited period. Start Saving Now →